National Cancer Institute; Notice of Closed Meeting, 51640 [07-4382]

Download as PDF 51640 Federal Register / Vol. 72, No. 174 / Monday, September 10, 2007 / Notices Agenda: To review and evaluate grant applications. Place: Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817. Contact Person: Marvin L. Salin, PhD, Scientific Review Administrator, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 7073, Bethesda, MD 20892–8329, 301–496– 0694, msalin@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel, NCI Small Grant Program. Date: November 6–7, 2007. Time: 8 a.m. to 1 p.m. Agenda: To review and evaluate grant applications and/or proposals. Place: Renaissance M Street Hotel, 1143 New Hampshire Avenue, NW., Washington, DC 20037. Contact Person: Irina V. Gordienko, PhD, Scientific Review Administrator, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 7073, Bethesda, MD 20892–8329, 301–594– 1566, gordienkoiv@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel, Small Grants Program for Cancer Epidemiology. Date: November 29–30, 2007. Time: 8:30 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Marriott Bethesda North Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD 20852. Contact Person: Joyce C. Pegues, PhD, Scientific Review Administrator, Special Review and Logistics Branch, Division of Extramural Activities, NIH National Cancer Institute, 6116 Executive Boulevard, Room 7149, Bethesda, MD 20892–8329, 301–594– 1286, peguesj@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: August 30, 2007. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–4381 Filed 9–1–07; 8:45 am] BILLING CODE 4140–01–M Name of Committee: National Cancer Institute Special Emphasis Panel, Rapid Access to Intervention Development. Date: October 9–10, 2007. Time: 8:30 a.m. to 5 p.m. Agenda: To evaluate the Rapid Access to Intervention Development Portfolio. Place: Bethesda Marriott, Pooks Hill, 5151 Pooks Hill Road, Bethesda, MD 20814. Contact Person: Phyllis G. Bryant, Executive Secretary, Program Analyst, Developmental Therapeutics Program, National Cancer Institute, NIH, 6130 Executive Boulevard, Rm. 8022, Bethesda, MD 20892, (301) 496–8720. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394 Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: August 30, 2007. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–4382 Filed 9–7–07; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health ebenthall on PRODPC61 with NOTICES is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate proposals for support through the RAID program by making available to the research community, on a competitive basis, NCI new agent development contract resources for the preclinical development of drugs and biologics. The outcome of the evaluation will be a decision whether NCI should support the request and make available contract resources for support through the RAID program to the research community and NCI new agent development for the preclinical development of drugs and biologics. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. National Cancer Institute; Notice of Closed Meeting BILLING CODE 4140–01–M Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2) notice VerDate Aug<31>2005 15:27 Sep 07, 2007 Jkt 211001 PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel, CA 07–506: ‘‘A Data Resource for Analyzing Blood & Marrow Transplants (U24)’’. Date: October 1, 2007. Time: 2 p.m. to 4 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, 6116 Executive Boulevard, Room 8109, Rockville, MD 20852, (Telephone Conference Call). Contact Person: Sonya Roberson, PhD, Scientific Review Administrator, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8109, Bethesda, MD 20892, 301–594–1182, robersos@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel, Cellular Oncology (SEP). Date: October 2–3, 2007. Time: 9 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda Marriott, Pooks Hill, 5151 Pooks Hill Road, Bethesda, MD 20814. Contact Person: Shakeel Ahmad, PhD, Scientific Review Administrator, Research Programs Review Branch, National Cancer Institute, Division of Extramural Activities, 6116 Executive Boulevard, Room 8137, Bethesda, MD 20892–8328, (301) 594–0114, ahmads@mail.nih.gov. Name of Committee: National Cancer Institute Initial Review Group, Subcommittee I—Career Development. Date: October 25, 2007. Time: 9 a.m. to 8 p.m. Agenda: To review and evaluate grant applications. Place: Crowne Plaza Washington Silver Spring, 8777 Georgia Avenue, Silver Spring, MD 20910. Contact Person: Robert Bird, PhD, Scientific Review Administrator, Resources and Training Review Branch, National E:\FR\FM\10SEN1.SGM 10SEN1

Agencies

[Federal Register Volume 72, Number 174 (Monday, September 10, 2007)]
[Notices]
[Page 51640]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-4382]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2) notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The purpose of this meeting is to evaluate 
proposals for support through the RAID program by making available to 
the research community, on a competitive basis, NCI new agent 
development contract resources for the preclinical development of drugs 
and biologics. The outcome of the evaluation will be a decision whether 
NCI should support the request and make available contract resources 
for support through the RAID program to the research community and NCI 
new agent development for the preclinical development of drugs and 
biologics. The research proposals and the discussions could disclose 
confidential trade secrets or commercial property such as patentable 
material, and personal information concerning individuals associated 
with the proposed research projects, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Institute Special Emphasis 
Panel, Rapid Access to Intervention Development.
    Date: October 9-10, 2007.
    Time: 8:30 a.m. to 5 p.m.
    Agenda: To evaluate the Rapid Access to Intervention Development 
Portfolio.
    Place: Bethesda Marriott, Pooks Hill, 5151 Pooks Hill Road, 
Bethesda, MD 20814.
    Contact Person: Phyllis G. Bryant, Executive Secretary, Program 
Analyst, Developmental Therapeutics Program, National Cancer 
Institute, NIH, 6130 Executive Boulevard, Rm. 8022, Bethesda, MD 
20892, (301) 496-8720.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394 Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: August 30, 2007.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 07-4382 Filed 9-7-07; 8:45 am]
BILLING CODE 4140-01-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.